Flossbach Von Storch SE Reduces Stock Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Flossbach Von Storch SE lowered its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,259,631 shares of the company's stock after selling 147,212 shares during the period. BioNTech makes up approximately 1.7% of Flossbach Von Storch SE's holdings, making the stock its 21st largest holding. Flossbach Von Storch SE owned about 1.78% of BioNTech worth $387,882,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. FMR LLC raised its holdings in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after acquiring an additional 1,401,547 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets bought a new position in BioNTech in the 4th quarter worth $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in BioNTech by 632.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after buying an additional 433,388 shares during the period. Finally, Capital International Investors boosted its holdings in BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after buying an additional 394,434 shares during the period. 15.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BNTX shares. HC Wainwright reissued a "buy" rating and set a $138.00 price objective on shares of BioNTech in a report on Wednesday, June 25th. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. Truist Financial reiterated a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, The Goldman Sachs Group began coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price for the company. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $137.91.

BioNTech Price Performance

BioNTech stock traded down $1.03 during midday trading on Friday, reaching $112.89. The company's stock had a trading volume of 521,908 shares, compared to its average volume of 942,367. BioNTech SE Sponsored ADR has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The stock's 50 day simple moving average is $103.40 and its 200 day simple moving average is $106.86. The firm has a market capitalization of $27.14 billion, a PE ratio of -33.20 and a beta of 1.29.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.